Kubota Pharmaceutical Holdings Co. Ltd.

Kubota Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical and medical device business worldwide. Its products include eyeMO, a remote retinal monitoring device for home-based and patient self-monitoring optical coherence tomography, and a NASA high-resolution version OCT device. The company also provides Emixustat HCI compounds for Stargardt disease in Phase 3 clinical trials, as well as for proliferative diabetic retinopathy and diabetic macular edema in Phase 2 clinical trials. Founded in 2002, it is headquartered in Minato, Japan.